U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343960) titled 'A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment' on Jan. 07.
Brief Summary: The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).
Study Start Date: Feb. 23
Study Type: INTERVENTIONAL
Condition:
Moderate Hepatic Impairment
Intervention:
DRUG: Capivasertib
Capivasertib will be administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curated by HT Syndi...